



This is a repository copy of *Cognitions and behaviours of general practitioners in France regarding HPV vaccination : a theory-based systematic review*.

White Rose Research Online URL for this paper:
<https://eprints.whiterose.ac.uk/167917/>

Version: Accepted Version

Article:

Escriva-Boulley, G., Mandrik, O. orcid.org/0000-0003-3755-3031, Préau, M. et al. (2 more authors) (2020) Cognitions and behaviours of general practitioners in France regarding HPV vaccination : a theory-based systematic review. *Preventive Medicine*. 106323. ISSN 0091-7435

<https://doi.org/10.1016/j.ypmed.2020.106323>

Article available under the terms of the CC-BY-NC-ND licence
(<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

**Cognitions and behaviours of general practitioners in France regarding HPV
vaccination: a theory-based systematic review**

Géraldine Escriva-Boulley¹, Olena Mandrik², Marie Préau¹, Rolando Herrero³,
Patricia Villain^{4*}

¹Laboratoire GRePS (EA 4163), Université Lyon 2, 69676, Bron, France

²The University of Sheffield, School of Health and Related Research (ScHARR), Health
Economic and Decision Science (HEDS), Sheffield S1 4DA, United Kingdom

³Prevention and Implementation Group, Early Detection and Prevention Section,
International Agency for Research on Cancer. World Health Organization (IARC – WHO),
69372, Lyon, France

⁴Screening Group, Early Detection and Prevention Section, International Agency for
Research on Cancer. World Health Organization (IARC – WHO), 69372, Lyon, France

*Corresponding author

Dr. Patricia Villain

Screening Group, Early Detection and Prevention Section

International Agency for Research on Cancer (WHO)

150 cours Albert Thomas, 69372 Lyon Cedex 08, France

E-Mail: villainp@iarc.fr; Tel: +33-472738440; fax: +33-472738518

Disclaimer: Where authors are identified as personnel of the International Agency for
Research on Cancer / World Health Organization, the authors alone are responsible for the
views expressed in this article and they do not necessarily represent the decisions, policy or
views of the International Agency for Research on Cancer / World Health Organization

1 **Abstract**

2

3 Human papillomavirus (HPV) vaccination is safe and efficacious to prevent persistent HPV
4 infection, precancerous anogenital lesions and cervical cancer. However, in countries where
5 vaccination programmes are implemented outside of schools, such as France, reaching high
6 HPV vaccination coverage of the target population is challenging. Many studies have been
7 performed in France to assess cognitions of general practitioners' (GPs) regarding HPV
8 vaccination. However, the evidence is not consistent about which cognitions are key. To
9 provide a comprehensive overview, we performed a systematic review of studies conducted in
10 France on GPs' cognitions regarding HPV vaccination and used the reasoned action approach
11 to extract and synthesize data. The systematic search was performed up to July 2020 in
12 Medline via PubMed, PsycINFO, PsycARTICLES, Embase, CINAHL Plus, Web of Science,
13 Pascal and Francis databases. Grey literature was searched for in the French Public Health
14 Database, Cairn. Info, yahoo.fr, and Google Scholar. Twenty-five scientific publications were
15 selected based on eligibility criteria and assessed for quality. Our qualitative synthesis
16 highlights that although 73% of GPs report recommending HPV vaccination, up to 50%
17 would not recommend it because of concerns, including changes in patients' health
18 behaviours and doubts about safety and/or efficacy. GPs' injunctive norms, i.e. trust in
19 institutional information, were shown to be associated positively with GPs' willingness to
20 recommend HPV vaccination. Parents' fears, girls' age, and potential connection with
21 sexuality do not seem to affect GPs' recommendations. These results will inform the
22 development of a professional educational intervention targeting GPs in France.

23

24 **Keywords:** General Practitioners, Reasoned Action Approach, HPV vaccination, France

25

1 **Introduction**

2 Human papillomavirus (HPV) vaccination has been shown to be highly effective to reduce the
3 prevalence of persistent infections with targeted HPV types and the incidence of high-grade
4 precancerous cervical lesions. Thus, it is currently being implemented in many countries,
5 though with variable coverage rates ¹. In some high-income settings, such as Canada and the
6 United Kingdom, HPV vaccination coverage can reach more than 80%. It is generally much
7 lower in countries where almost all vaccinations are delivered outside of schools such as the
8 United States and France ¹. In France, where general practitioners (GPs) are responsible for
9 counselling and vaccinating adolescent girls, HPV vaccination coverage of the target
10 population, i.e. girls aged 11-14 year since 2012, has not exceeded 30% since its
11 implementation ². Barriers and facilitators to HPV vaccination have been intensely studied in
12 France ³⁻⁵. For French parents and young girls, the main barriers regarding HPV vaccination
13 are concerns about serious side effects ³⁻⁵. Socioeconomic determinants have been shown to
14 influence HPV vaccination uptake with a lower uptake observed in more deprived groups ⁴.
15 Similarly to others primary care professionals, the HPV vaccination decision of French
16 parents is driven by the recommendations of their GPs ⁵⁻⁷. GPs' barriers mainly concern the
17 efficacy and safety of HPV vaccination, and also relate to the national recommendations
18 regarding HPV vaccination age and groups ^{5,6}. The French National Cancer Institute and/or
19 other national agencies have implemented interventions to address GPs' barriers ^{8,9}. Changes
20 in the national recommendations regarding the age of girls did not lead to an increase in HPV
21 vaccination uptake and it is too early to report on the efficacy of extending HPV vaccination
22 to boys ^{9,10}. The provision of information about HPV vaccination to GPs has been reinforced
23 since 2017 ¹¹. Although they have not been formally evaluated, these actions are speculated to
24 contribute to the upward trend in coverage observed in France since 2015 ⁹. The gaps and the
25 apparent contradiction in the evidence suggest that some important determinants regarding
26 French GPs' cognitions might have been missed.


27 A systematic review focusing on French GPs' cognitions and going beyond only knowledge
28 and attitude, which are usually reported, will fill this research gap ^{12,13}. Using a behaviour
29 theory as a framework to extract evidence can provide a more comprehensive overview of
30 these cognitions. We chose to conduct a reasoned action approach (RAA) theory-based
31 systematic review of studies performed in France in order to provide a comprehensive
32 overview of French GPs' cognitions related to HPV vaccination. The RAA is the most recent
33 derivative of the theory of planned behaviour, which has been the most used theoretical

1 framework to explain and predict health practitioners' intentions and behaviours regarding
2 HPV vaccination ¹⁴⁻¹⁶. In addition, the RAA provides a more detailed framework with each of
3 the cognitions of the theory of planned behaviour represented by pairs of distinct, but related,
4 subcomponents, which have been shown to be important in predicting and explaining
5 behaviour ^{16,17}. The RAA differentiates the following cognitions (Fig. 1):

- 6 • Instrumental (i.e. perceived outcomes of behaviour adoption) or experiential (feelings
7 associated with behaviour) attitudes;
- 8 • Injunctive (i.e. perceived expectations of important referent individuals or social
9 groups) and descriptive (i.e. perceptions of what important referent individuals or
10 social groups do) norms;
- 11 • Perceived behavioural control's capacity (i.e. individuals' confidence, beliefs about
12 the necessary skills and abilities they have to perform the behaviour) and autonomy
13 (i.e. individuals' beliefs that they have control over the behaviour).

14 We used this framework to (i) report GPs' cognitions and beliefs, and (ii) examine the
15 impacts of these cognitions on GPs' behaviours. The impact of background variables related
16 to GPs, i.e. self-related, contextual, or sociodemographic, was also investigated, because they
17 could be influential to French GPs' cognitions and/or behaviours regarding HPV vaccination
18 (Fig. 1) ¹². The results of this review will inform the design of an educational intervention on
19 HPV vaccination targeting GPs in France.

20
21
22
23



1

2 **Figure 1.** Theoretical framework used in the review based on the reasoned action approach (RAA)¹⁶. In this theory, behaviour is driven by intention, which
 3 in turn is driven by instrumental and experiential attitudes towards the behaviour, injunctive and descriptive norms, and PBC's capacity and autonomy.
 4 Intention regarding HPV vaccination was not assessed in the review, because no data were available.

5 GP= general practitioner; PBC = perceived behavioural control

6

1 **Methods**

2 We used the PRISMA statement and the checklist to report explicitly and comprehensively all
3 the recommended components ¹⁸.

4 **Study search and selection**

5 The systematic search was performed by PV up to December 2018 in the following
6 databases: Medline via PubMed, PsycINFO, PsycARTICLES, Embase, CINAHL plus, Web
7 of Science, Pascal and Francis. The search for grey literature was performed by both GB and
8 PV in the French Public Health Database (Banque de données en santé publique), Cairn.Info,
9 yahoo.fr and Google Scholar. Search updates from December 2018 to July 2020 were
10 conducted by PV. The full research query in Medline via PubMed is available in Appendix,
11 Table A.1.

12 To be considered for inclusion, titles/abstracts and then full texts were required to meet the
13 following criteria: (a) published in any language, (b) the study population was GPs or
14 included GPs, (c) used quantitative (self-reported questionnaire) and/or qualitative (semi-
15 structured interview, focus group) method, (c) reported outcomes related to any information
16 regarding GPs' cognitions and/or behaviours related to HPV vaccination, (d) based in France
17 or included France among other countries, and (e) was an original study and either a peer-
18 reviewed article or a medical dissertation. Studies were excluded when (a) focused on
19 psychometric validation of questionnaires, or (b) were review, conference abstract, opinion
20 and/or a published survey that did not provide a full description of the methodology and
21 results or (c) was a medical dissertation whose related results were published in a peer-
22 reviewed article, which was part of the review.

23 **Data extraction**

24 A data extraction form and coding method was developed and tested first with some of the
25 included studies. The variables of interest were those presented in the tables in the Result
26 section or the Appendix. The variables were descriptive and included studies characteristics,
27 GPs' characteristics, GPs' cognitions as reported in the RAA model (Fig. 1) and background
28 variables that have been shown to influence primary care professionals' behaviour regarding
29 HPV vaccination ¹² (Fig. 1).

30 We also extracted all variables to explore a possible relationship or an association between a)
31 GPs' attitudes, norms, perceived behavioural control and either cognitions or behaviour

1 regarding HPV vaccination b) background variables and either GPs' attitude or behaviour
2 regarding HPV vaccination.

3 Data from all included full-text publications were identified and extracted by two
4 investigators (GEB and PV). Any disagreement in data extraction was resolved by consensus.

5 **Assessment of study quality**

6 Two of the authors independently assessed the methodological quality of the included articles
7 using the Newcastle-Ottawa quality assessment scale (NOS) for cohort studies adapted for
8 cross sectional studies and the Critical Appraisal Skills Programme (CASP) framework for
9 qualitative articles^{13,19,20}. An additional column was added to the NOS tool to highlight
10 articles. Any disagreement in quality grading was resolved by consensus.

11 **Synthesis**


12 Because of heterogeneity in data measurements and the outcomes, qualitative synthesis was
13 applied to synthesize the data²¹. No study was excluded based on its quality. However when
14 synthesized the findings and when appropriate, the research outcomes were evaluated taking
15 into account the quality of the studies involved.

16

1 **Results**

2 We identified 2361 abstracts through our systematic search and 73 additional through a non-
3 systematic search (Fig. 2). We screened 1512 abstract for eligibility. We assessed 78 records
4 based on full text evaluation. Twenty-five studies were included in the synthesis (Fig. 2).

5
6



7
8
9

Figure 2. Studies included in the review based on the PRISMA flow diagramme ¹⁸

1 **Description of the included articles**

2 Among the 25 studies identified for this review²²⁻⁴⁶, 18 reported quantitative and seven
3 qualitative designs (Table 1). The majority of the studies were conducted either before 2011
4^{23,29,34,36,39-41,44} with some around 2007-2008 i.e. the period where HPV vaccination was
5 implemented in France^{23,29,36,39,40}, or over the 2011–2015 period^{22,24,25,27,30,32,33,37,38,42,46}. The
6 most recent studies were conducted in 2016^{26,31,35,43} or in 2019^{28,45}. The sample size ranged
7 from ten to 31 GPs in the qualitative studies and from 96 to 1598 in the quantitative studies.
8 Except for five articles in which the participants represented a national panel^{22,27,35,44,46}, the
9 studies included participants from local panels. Only one study used random sampling to
10 select participants³⁵.

11 The quality of the included articles varied widely, with ten articles^{24,30,32-34,38,40,42,43,46},
12 considered at low risk (i.e., high-quality studies), six^{22,27,36,37,39,44} at moderate risk (i.e.,
13 moderate-quality studies), and nine at high risk of bias^{23,25,26,28,29,31,35,41,45} (i.e., low-quality
14 studies) (Appendix, Tables A.2 and A.3).

15 Although the characteristics of the participants were not systematically reported in the
16 articles, those that did report the characteristics described the GP study groups as mainly men
17 (more than 50% in 20 of the 25 articles), middle-aged (mean age range: 42.3–54 years)
18^{23,24,26,28,30,31,33-37,39,40,43-45}, with more than 10 years of experience in general practice
19^{24,31,37,41,43}, working mainly in urban and suburban areas^{23-26,28,30,32-34,36-39,41,43}, and with a
20 workload of between 3000 and 6000 consultations per year for more than 50% of GPs
21^{22,27,32,33,42} (Appendix, Table A.4).

22

1 **Table 1.** Characteristics of studies included in the review

Author (publication year) Year(s) of data collection	Document^a	Study design	Measurement	Participants /Invited^b (Type of recruitment)	Aim	Risk of bias^c
Agrinier (2017) ²² 2013–2014	Article	Quantitative	Self-reported questionnaire	1038/1712 (National panel)	To measure discrepancies between vaccination recommendations by GPs for their patients and practices for their children	Moderate
Barjhoux (2009) ²³ 2008	Medical dissertation	Quantitative	Self-reported questionnaire	278/1200 (Local panel)	To evaluate the modalities and difficulties encountered by GPs when offering the vaccine to patients	High
Bouvret (2016) ²⁴ 2014–2015	Article	Quantitative	Self-reported questionnaire	96/140 (Local panel)	To assess opinions, practices, and difficulties of GPs regarding HPV vaccination	Low
Casimont (2015) ²⁵ 2014	Medical dissertation	Qualitative	Interview	10 (Local panel)	To describe opinion of GPs about changes in strategies to prevent cervical cancer	High
Chauvet (2016) ²⁶ 2016	Medical dissertation	Quantitative	Self-reported questionnaire	143/495 (Local panel)	To evaluate tools that aim to help GPs to deliver information about HPV vaccination	High

Author (publication year) Year(s) of data collection	Document^a	Study design	Measurement	Participants /Invited^b (Type of recruitment)	Aim	Risk of bias^c
Collange (2016) ²⁷ 2014	Article	Quantitative	Self-reported questionnaire	1598/1712 (National panel)	To study GPs' perceptions of HPV vaccination risks and efficacy and their recommendation behaviour; and the relative importance of factors associated with the frequency of their recommendations	Moderate
Degoue (2019) ²⁸ 2018-2019	Medical dissertation	Quantitative	Self-reported questionnaire	337 (Local panel)	To describe GPs' practice regarding HPV vaccination	High
Erpeldinger (2012) ²⁹ 2009	Article	Quantitative	Self-reported questionnaire	518/1193 (Local panel)	To describe the knowledge of GPs on infection with HPV and Gardasil®, and to determine the impact of training and information on knowledge and the attitude towards this vaccine	High
Gougenheim-Fretin (2014) ³⁰ 2013	Medical dissertation	Qualitative	Interview/focus group	10 (Local panel)	To highlight the reluctance of GPs toward HPV vaccination	Low
Houdjal (2017) ³¹ 2016	Medical dissertation	Qualitative	Interview	12 (Local panel)	To highlight GP representations of HPV vaccination	High

Author (publication year) Year(s) of data collection	Document^a	Study design	Measurement	Participants /Invited^b (Type of recruitment)	Aim	Risk of bias^c
Killian (2016) ³² 2013–2014	Article	Quantitative	Self-reported questionnaire	693/2839 (Local panel)	Comparison of GPs' HPV immunization practices for their patients and their children	Low
Lamirand (2015) ³³ 2015	Medical dissertation	Qualitative	Interview	11 (Local panel)	To describe impacts of the media and new recommendations about HPV vaccination on GPs' practice	Low
Lasset (2014) ³⁴ 2010	Article	Quantitative	Self-reported questionnaire and interview	271/290 (Local panel)	To investigate the evolution of practices and opinions regarding HPV vaccination among GPs	Low
Leicht (2016) ³⁵ 2016	Medical dissertation	Quantitative	Self-reported questionnaire	171/350 (National panel)	To identify obstacles of GPs in France for HPV vaccination	High
Lutringer-Magnin (2011) ³⁶ 2007–2008	Article	Quantitative	Self-reported questionnaire and interview	279/5973 (Local panel)	To examine the perceptions, attitudes, and practices of GPs in relation to HPV vaccination	Moderate

Author (publication year) Year(s) of data collection	Document^a	Study design	Measurement	Participants /Invited^b (Type of recruitment)	Aim	Risk of bias^c
Manolitsi (2012) ³⁷ 2012	Medical dissertation	Quantitative	Self-reported questionnaire	145/932 (Local panel)	To examine and to understand the obstacles of GPs regarding HPV vaccination	Moderate
Martinez (2016) ³⁸ 2013	Article	Qualitative	Interview/focus group	36/622 (Local panel)	To conduct an exploratory qualitative study with GPs to identify determinants of their commitment to vaccination	Low
Pelissier (2008) ³⁹ 2007	Article	Quantitative	Self-reported questionnaire	252/545 (Local panel)	To describe prevention behaviours and to examine perceptions of HPV vaccination	Moderate
Piana (2009) ⁴⁰ 2008	Article	Quantitative	Self-reported questionnaire	359/1000 (Local panel)	To assess the standpoint of GPs regarding HPV vaccination and to evaluate the factors associated with a favourable standpoint	Low
Plessis (2012) ⁴¹ 2009–2010	Article	Qualitative	Interview/focus group	16/19 (Local panel)	To better understand GPs' decisions about HPV vaccination and their role in cervical cancer	High
Raude (2016) ⁴² 2013-2014	Article	Quantitative	Self-reported questionnaire	1582/1712 (Local panel)	To improve the understanding of the role of institutional trust in practices related to vaccination	Low

Author (publication year) Year(s) of data collection	Document^a	Study design	Measurement	Participants /Invited^b (Type of recruitment)	Aim	Risk of bias^c
Sadki (2016) ⁴³ 2016	Medical dissertation	Qualitative	Interview	17/28 (Local panel)	To highlight GPs' opinions and practices about HPV vaccination and their attitude toward reluctance to vaccination	Low
Thierry (2016) ⁴⁴ 2010	Article	Quantitative	Self-reported questionnaire	363/706 (National panel)	To evaluate the vaccine coverage, according to eligibility for vaccination in a sample of girls who were seen in general practices in France	Moderate
Tutala (2019) ⁴⁵ 2018-2019	Medical dissertation	Quantitative	Self-reported questionnaire	216/4148 (Local panel)	To evaluate the role of health practitioners regarding HPV vaccination in Occitanie region	High
Verger (2015) ⁴⁶ 2013–2014	Article	Quantitative	Self-reported questionnaire	1582/1712 (National panel)	To assess the prevalence of vaccine hesitancy among GPs through the frequency of their vaccine recommendations, and the determinants of these recommendations	Low

1 GP = general practitioner; HPV = human papillomavirus

2 ^aPeer-reviewed article or medical dissertation

3 ^bInvited to participate in the study, where available

4 ^cAppendix, Tables A.2 and A.3

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

GPs’ attitudes, norms, perceived behavioural control, and underlying beliefs regarding HPV vaccination

GPs’ cognitions regarding HPV vaccination are summarized in table 2. Attitudes^{23-25,27-31,34-46} and perceived behavioural control towards HPV vaccination^{23-26,28,30,31,33-46} were evaluated in a total of 21 studies each, whereas norms were examined in only 11 articles^{24,25,31,34,36,38,40-43,46}. None of the articles distinguished between the subcomponents of each cognition when reporting the results.

Attitudes and underlying beliefs

Among the 21 studies reporting GPs’ attitudes, we identified that one reported GPs’ experiential attitudes only²⁵, nine reported instrumental attitudes only,^{23,27,35,38,39,41,42,44,46} and 11 reported both^{24,28-31,34,36,37,40,43,45} (Table 2). Experiential attitudes were reported mostly in terms of favourable versus unfavourable opinions towards HPV vaccination, confidence versus concern, worry or doubt, and/or enthusiasm^{24,25,28-31,34,36,37,40,43,45}. Instrumental attitudes were reported in terms of trust regarding efficacy and security, perceptions of the efficacy of HPV vaccination, its benefits, its usefulness and/or its risks represented by fear of side effects, especially in relation to autoimmune diseases^{23,24,27-31,35-38,40,42-46}. Instrumental attitudes were also reported by assessing beliefs related to the impact of HPV vaccination on other health behaviours, i.e., cervical cancer screening, condom use, and/or sexual behaviours^{24,30,31,34,35,37,40,41}.

The results showed that GPs found HPV vaccination to be useful and necessary^{27,28,31,42-44,46}. When assessed, and independently of study quality, more than 74% of GPs were in favour of or approved of HPV vaccination^{24,25,28,31,34,36,37,40,43,45}. When study quality was taken into account, i.e. reported percentage adjusted to reflect overall quality of the studies, 21%–35% of GPs reported doubts about the clinical benefits or efficacy of HPV vaccination^{23,24,27,37} and about 30–50% reported worries or concerns about side effects^{24,27,28,30,35-37,40,44}. More specifically, rates of GPs with worries and concerns were 19–50% in high-quality studies^{24,30,40}, 23–60% in moderate-quality studies^{27,36,37,44}, and 23–34% in low-quality studies^{28,35}. The date of study did not seem to explain these results. Three low-quality studies reported that up to 10% of GPs even considered HPV vaccination to be dangerous^{23,28,31}. In studies performed before 2015, for up to 61% of GPs these doubts about efficacy and benefits/risks

1 were linked to the “novelty” of HPV vaccination and the relatively short period since the
2 introduction of the vaccine^{23,24,27,37,39,41}. Irrespective of study quality and date, 16–29% of
3 GPs believed that HPV vaccination would decrease patients’ participation in cervical cancer
4 screening^{24,30,31,37,40}, 16–24% of GPs reported that HPV vaccination would decrease the use
5 of condoms^{24,30,37,40,41} and 5-10% that it would lead to taking sexual risks and/or encourage
6 premature sexuality^{30,34,35,40}. Furthermore, in five articles mostly with high^{23,25,29,41} to
7 moderate³⁹ risk of bias, GPs reported that screening and/or condom use are more effective
8 than HPV vaccination^{23,25,29,39,41}.

9 *Norms and underlying beliefs*

10 Regarding norms, influence of pairs was approached in two studies^{31,38} and injunctive norms
11 were mainly assessed^{24,25,31,34,36,38,40-43,46} (Table 2) These norms included GPs’ perceptions of
12 their role in public health policies, the need to follow health authorities’ recommendations,
13 and trust in institutional information. Overall, 81–94.5% of GPs trusted that institutional
14 information (i.e., from the ministry of health, health agencies, scientific sources, and the
15 opinions of scientists and specialist physician colleagues) about the benefits and risks of
16 immunization was reliable^{24,25,31,34,36,38,40-43,46}. HPV vaccination was seen as a requirement for
17 preventive medicine and a benefit for public health^{34,36,38,41}. For instance, the beneficial
18 effects of vaccination on primary prevention of HPV and public health were highlighted by
19 60% of GPs^{34,36}. GPs emphasized their role in public health, which consisted of informing
20 patients about recommended vaccines, explaining, convincing, and justifying the vaccination
21 recommendations, addressing discussions about sexuality, and vaccinating their patients^{38,41}.
22 GPs also stated that they vaccinated their patients to be in line with recommendations
23^{25,31,40,41,43}.

24

1 **Table 2.** General practitioners' cognitions regarding HPV vaccination

Type	Subcomponents ^a
Attitude	<p>Experiential attitudes^{24,25,28-31,34,36,37,40,43,45}</p> <ul style="list-style-type: none"> ➤ In favour or approve HPV vaccination^{24,25,28,31,34,36,37,40,43,45} : > 74% ➤ Prudent, enthusiast, doubt, worried^{29,30} <p>Instrumental attitudes^{23,24,27-31,34-46}</p> <ul style="list-style-type: none"> ➤ Trust in efficacy and safety⁴⁵: 81% ➤ Useful and necessary^{27,28,31,42-44,46} : 75% ➤ Doubt about clinical benefits or efficacy^{23,24,27,37}: 21% -35% ➤ Worried about potential side effects and risks^{24,27,28,30,35-37,40,44} : 30% - 50% ➤ HPV vaccine is dangerous^{23,28,31}: < 10% ➤ Other consequences^{24,30,31,34,35,37,40,41} <ul style="list-style-type: none"> ○ Decrease of cervical cancer screening^{24,30,31,37,40} : 16% -29% ○ Decrease of condom use^{24,30,37,40,41}: 16%-24% ○ Encourage riskier sexual behaviour or premature sexual relation^{30,34,35,40} : 5%-10%
Norms	<p>Injunctive norms^{24,25,31,34,36,38,40-43,46}</p> <ul style="list-style-type: none"> ➤ GP's role regarding public health policies^{38,41} ➤ Need to follow health authorities' recommendations^{25,31,40,41,43} ➤ Trust in institutional information provided by official sources^{24,25,31,34,36,38,40-43,46} : 81-94.5% ➤ Public health^{34,36,38,41} : 60% <p>Descriptive norms</p> <ul style="list-style-type: none"> ➤ Rely on pairs opinion and practice to decide to vaccinate^{31,38}
Perceived Behavioural Control	<p>Capacity^{24,26,30,35,39,40,42,44-46}</p> <ul style="list-style-type: none"> ➤ Have enough information about HPV vaccination and related subjects^{24,30,35,39,40,45} : > 68% ➤ Feel confident to inform about HPV vaccination^{26,39,42,45,46} : 19% to 88% ➤ Feel able to implement recommendations³⁹: 70% ➤ Feel comfortable with adolescents care⁴⁴: 95% <p>Autonomy (essentially barriers)^{23-25,28,30,31,33,34,36-38,41,43,45}</p> <ul style="list-style-type: none"> ➤ Parents²⁸ : 56% ➤ Parents' fear of side effects^{24,25,28,30,31,36,37,43}: > 60% ➤ Age of girls^{23,25,30,31,33,34,36,37,43} ➤ Scarcity of pre-adolescents or adolescents' consultations^{30,33,34,43} ➤ Socio-cultural characteristics of patients as barriers^{23,24,30,33,37,41}: 17.5% to 25% ➤ Lack of time^{23,25,30,38,43,45}

2 HPV= human papillomavirus

3 ^aPercentage of general practitioners was reported when available

1 ***Perceived Behavioural control and underlying beliefs***

2 ***Capacity***

3 Except for one study, which did not indicate rates³⁰, more than 68% of GPs felt that they
4 were well-informed about HPV and HPV vaccination^{24,30,35,39,40,45}. GPs felt confident in
5 justifying vaccine recommendations and in explaining the utility of the vaccine (up to 88%)
6 and its safety (up to 77%)^{26,39,42,45,46}. However, this rate was lower (up to 58%), when
7 confidence in explaining the role of vaccine adjuvants was investigated^{26,42,45,46}. GPs reported
8 being comfortable with having adolescents as patients⁴⁴.

9 ***Autonomy***

10 Parents' fear of side effects of HPV vaccination is one of the most important barriers, reported
11 by more than 60% of GPs^{24,25,28,30,31,36,37,43}.

12 GPs explained these fears by the relatively short period since the introduction of the vaccine
13^{24,43} and controversies about vaccination in general or about specific vaccines, such as those
14 against hepatitis B virus, H1N1 influenza virus, and HPV^{24,25,30,31,39,41}. Independently of their
15 quality, studies reported high variability in the rate of GPs who considered the socio-cultural
16 characteristics of patients and their parents (e.g., religion and personal conviction) to be
17 important barriers (17.5–25%)^{23,24,30,33,37,41}.

18 The main practice-related barriers reported were the age of girls^{23,25,30,31,33,34,36,37,43} and the
19 scarcity of consultations with adolescents^{30,33,34,43}. Before 2012, when vaccination was
20 recommended for girls aged 14 years, 28–72% of GPs would have preferred to vaccinate
21 against HPV at as young an age as possible (i.e., 11–14 years) to avoid having to discuss
22 sexually transmitted infections and sexuality^{23,36}. Indeed, addressing sexually transmitted
23 infections was reported as an issue for 11–31% of GPs^{23,34,36,37}. After 2012, when HPV
24 vaccination became recommended for girls aged 11–14 years, GPs no longer felt an
25 obligation to discuss sexuality, and therefore they perceived this change as beneficial^{33,43}.
26 Nevertheless, some GPs continued to address sexuality as part of the information on HPV
27 vaccination or to satisfy parents' expectations and requests^{31,33,43}. This did not seem to be a
28 barrier anymore⁴⁵. Meanwhile, new issues were reported by GPs regarding younger ages of
29 patients: girls being too young to be concerned^{25,31,33}, having to rely on parents negative
30 decision as reported by 56% of GPs²⁸, and parents being insecure to talk about sexuality at
31 such young age and/or frightened of encouraging premature sexuality^{25,31,33,43}. These issues


1 affected GPs' practice as both parents and GPs had the tendency to delay HPV vaccination to
2 older ages (i.e. 14) ^{31,43}.

3 The scarcity of consultations with adolescents was perceived as a serious obstacle ^{30,33,34,43}.
4 Therefore, any reason for consultation (i.e., medical consultation other than vaccination,
5 certificate of fitness for sport) was reported to be used to propose the vaccine ^{25,30,43}.

6 **GPs' behaviours regarding HPV vaccination**

7 Main results are presented in Fig. 3 and in details in Appendix (Table A.5). In the more
8 recent studies of moderate to high quality and with larger number of participants, 73% of GPs
9 reported either always (46%) or often (27%) recommending HPV vaccination to the target
10 population ^{27,46}, and 72.9% of GPs reported proposing to vaccinate these girls against HPV ²⁴.

11



1

2 **Figure 3.** Association between general practitioners' cognitions and behaviour variables assessed in the review. Sens of arrow reflects which
 3 variable was used as dependent vs independent in the studies. Association was either not significant (X) or significant and either positive (+) or
 4 negative (-). Descriptive norms were not assessed. PBC = perceived behavioural control; HPV = human papillomavirus

1 **Impact of cognitions**

2 Five articles used quantitative methods to examine the effects of specific cognitions on the
3 behaviour of interest, essentially to recommend or propose^{24,26,27,42,46}. Five articles examined
4 the links between cognitions and dependent variables, i.e., experiential attitudes^{34,36,37,40},
5 vaccine hesitancy⁴², or perceived behavioural control⁴².

6 *Importance of instrumental attitudes*

7 Among attitudes tested, GPs' perceptions of risks, including change in patients' health
8 behaviour and doubts about vaccine utility/efficacy, were shown to be negatively associated
9 with proposing and recommending HPV vaccination^{24,27,42,46}. GPs' concerns about side
10 effects of HPV vaccination were shown to be negatively associated with favourable
11 (experiential) attitudes^{37,40}.

12 *Importance of injunctive norms*

13 Results from three studies of either moderate quality²⁷ or high quality^{42,46} were in favour of
14 a positive and significant association between trust and recommending HPV vaccination.
15 GPs' trust in institutional information showed a positive and significant association with HPV
16 vaccination recommendation, either directly⁴⁶ or indirectly and mediated through a decrease
17 in vaccine hesitancy⁴². Trust was also positively correlated with ability to explain the utility,
18 safety, and adverse events of vaccination⁴². Beneficial effects of vaccination in public health
19 and its role in primary prevention were positively correlated with favourable (experiential)
20 attitudes³⁴.

21 *Perceived behavioural control: inconsistent results*

22 The impact of abilities on behaviour was contradictory from two high-quality studies.
23 Confidence in GPs' ability to explain the utility of vaccines, the safety of vaccines, and the
24 role of adjuvants in general (including HPV) was reported to be either associated (positively)
25 or not associated with recommendation of the vaccines^{42,46}. Ability to talk about sexuality
26 was positively associated with favourable opinions about HPV vaccination⁴⁰, but HPV
27 vaccine knowledge, by itself, seemed not to have effect on experiential attitudes³⁷.

28 When autonomy, i.e., barriers related to either patients or practice (i.e., reason for
29 consultation, age for vaccination, questions asked by patients, parents' presence and
30 reluctance to address sexuality, and necessity to address the issue of sexually transmitted

1 infections) were examined, they were not associated with GPs' recommendation ²⁷ and it is
2 not clear if it is associated with GPs' attitudes ^{36,37}.

3 **Impact of background variables on behaviours and experiential attitudes regarding** 4 **HPV vaccination**

5 Ten articles reported effects of background variables on behaviours and/or experiential
6 attitudes (i.e., favourable opinion), with age and gender being the most studied variables ²²⁻
7 ^{24,26,27,29,32,34,36,40} (Appendix, Table A.6).

8 When study quality was taken into account, results from studies assessing age of GPs
9 ^{23,24,26,27,29,36,40} showed that younger GPs were more favourable to proposing vaccination and
10 to vaccinating against HPV ^{24,36,40}. The results showed no significant association between
11 gender and behaviours or attitudes ^{23,24,26,27,29,36}, except in one high-quality article in which
12 men were more prone to have favourable opinions ⁴⁰. Practice-related variables (workload
13 reported as consultations or visits >100/week or >3000/year, consultation duration <20
14 minutes, seeing more women or children/teenagers) were positively associated with
15 favourable opinions and recommendation/vaccination ^{27,36,40}. HPV vaccination behaviour was
16 not affected by practice of alternative medicine (e.g., homeopathy, acupuncture), practice of
17 Pap smear or gynaecology, or recommendation of other vaccines, although these variables
18 were shown to affect favourable opinions towards HPV vaccination ^{24,26,29,36,40}. Variables that
19 were not related to behaviours or attitudes were type of practice (i.e., solo/group), number of
20 years of practice, cost of vaccine, and number of injections ^{24,26,32,36}.

1 **Discussion**

2 The use of the RAA theoretical framework to extract and analyse data offers new insights into
3 French GPs' cognitions and behaviours regarding HPV vaccination. Our review shows that, in
4 terms of attitude, these are fears of risks (i.e., concerns about safety and change of behaviour)
5 and doubts about utility/efficacy regarding HPV vaccination, which drive GPs' decisions
6 about whether to recommend HPV vaccination ^{24,27,42,46}. Taking into account that very strong
7 ethical norms are in place in GPs as a professional group, including the precautionary
8 principle, which is very well embedded in norms in France regarding public health ⁴⁷, it is
9 more likely that GPs with concerns and doubts, i.e., 30- 50% of GPs ^{23,24,27,28,30,35-37,40,44} will
10 neither propose nor recommend HPV vaccination to girls. This figure may even be
11 underestimated, because GPs' responses are potentially biased due to social desirability (GPs
12 respond what they think they should say) and/or wishful thinking (GPs respond what they
13 would like to be true). It is worth noting that the percentage of GPs with concerns and doubts
14 is very high and in line with the rate of unvaccinated adolescent girls in France, i.e. about
15 70% in 2019 ².

16 Although up to 88% of GPs report confidence in explaining the safety and efficacy of HPV
17 vaccination ^{26,39,42,45,46}, the percentage of GPs who will be able to answer related specific
18 questions is probably much lower, as reported in France and in other settings ^{45,48}. This result
19 together with the fact that up to 50% of GPs reports doubts and concerns regarding HPV
20 vaccination is intriguing. Indeed, reliable information related to HPV vaccination safety and
21 efficacy is easily accessible to GPs through authoritative health websites ¹¹. It is possible that
22 French GPs, who have been reported to work at least 50 hours a week, may not have time to
23 both access HPV vaccination-related information and attend continuing education ⁴⁹. Another
24 possibility, which might be also related to their heavy workload, is that GPs use heuristics to
25 process HPV-related information. These are mental shortcuts that enable them to make
26 decisions and process information more rapidly and based on incomplete, uncertain, or/and
27 peripheral information ⁵⁰. Heuristics have been shown to be part of health practitioners'
28 practice and driven by constraints such as time⁵¹. Moreover, it has been shown that heuristics-
29 based information is less resistant to counter-argument and less predictive of behaviour than
30 systematic processing ⁵⁰. It is thus possible that GPs when facing parents would not be able to
31 address parents' arguments and even recommend HPV vaccination, which is a driver for
32 parents to vaccinate ⁵⁻⁷. This may explain the discrepancy between the GP-reported
33 recommendation/vaccination rate (i.e. 70%) ^{24,27,46} and actual HPV vaccination rates (of less

1 than 30%), which is also reported in other settings ^{12,52}. The positive effect of higher (>3000
2 consultations/year) workload on GPs behaviour ²⁷ seems to contradict our hypothesis on time
3 constraints stated above. This threshold may be underestimated according to the average
4 number of consultations per GP per year i.e. 5100 -5800 ^{49,53}. Thus, instead of considering a
5 positive effect of high workload, we may assume that GPs with a workload lower than
6 average (e.g. semi-retired, working part-time or as substitutes), recommend less HPV
7 vaccination, what may be explained by seeing less patients including girls.

8 Our results suggest that the ways in which HPV vaccination-related information is currently
9 provided to GPs in France are not adequate. Vaccination teaching in the French medical
10 curriculum has shown some limitations ⁵⁴. Continuing medical education is not mandatory,
11 eventhough completing at least one training is part of the GPs' annual performance scheme.
12 Information tools, including continuing education, should be developed to favour less
13 heuristic processing of information and take into account GPs' constraints.

14

15 Our review highlights the central place of injunctive norms, i.e., trust in institutional
16 information, in positively affecting GPs' beliefs and behaviours regarding HPV vaccination
17 ^{42,46}. This is understandable because GPs are recognized as a professional group with shared
18 strong professional norms. Regarding descriptive norms, to the best of our knowledge, no
19 studies have yet explored in details the role of these norms in GPs' behaviours regarding HPV
20 vaccination, although they have been shown to be a driver in physicians' practice ⁵⁵. Future
21 work is needed in this field. Both the importance of HPV vaccination and the role of GPs in
22 public health should be highlighted when developing information tools and education
23 modules on HPV vaccination.

24 Parents' fear of side effects of HPV vaccination is reported by more than 60% of GPs as one
25 of the most important barriers to recommend and vaccinate ^{24,25,28,30,31,36,37,43}. Despite the
26 change of the target age group from 14 years to 11–14 years, the age of girls remains an issue
27 for GPs, raising even more concerns. The main reason is that HPV vaccination remains
28 strongly connected to sexuality or sexual behaviour, as reported in other settings, such as the
29 United States and Canada ^{12,52}. However, age/sexuality/parents fears does not seem to impact
30 GPs' recommendation decision regarding HPV vaccination (in our review). Vaccination
31 might be an issue due to girls' parents but GPs have a strategy in place i.e. vaccinate girls
32 later, at around age 14 years, which is also highlighted in other reviews ^{12,52}. This is
33 interesting as research has been developed in recent years focusing on patients as a barrier and

1 developing interventions to improve the abilities of health providers to recommend HPV
2 vaccination. Interventions using this approach have been shown to be effective ^{56,57} ; however
3 neither sustainability of these interventions nor their effects on GPs' cognitions have been
4 shown so far ⁵⁸. Moreover if motivational interviewing seems to be promising, time required
5 to do it properly and based on ethical principles render it difficult to be integrated in GPs'
6 busy schedule ⁵⁹.

7 Our results suggest that these are actually GPs themselves that could be considered as a
8 barrier to HPV vaccination and that research should centre on how HPV vaccination
9 information is effectively conveyed to them. While this study included only GP-related
10 interventions, the findings will be applicable to other primary care professionals (e.g. nurses),
11 in healthcare systems where the patient consultations are not limited to GPs ⁶⁰. Moreover,
12 taking into account that HPV vaccination of girls aged 11–14 years often seems to be delayed
13 to older ages and that sexuality always seems to be connected to this vaccination whatever the
14 age of the girl, one option to facilitate HPV vaccination would be to increase the age of the
15 target group to 15–18 years. This is supported by recent scientific evidence obtained by our
16 group showing efficacy of HPV vaccination for this age group with a two-dose schedule ⁶¹,
17 but should be balanced against the possibility of missing opportunities to vaccinate before
18 sexual debut among early initiators.

19 Our study has the usual limitations of synthesising evidence from retrospective surveys based
20 on self-reporting, including recall bias, social desirability bias, and wishful thinking bias. It
21 should be highlighted that taking into account the nature of the population surveyed, i.e., GPs,
22 social desirability and wishful thinking may be particularly important. The included studies
23 covered a twelve year period (Table 1), over which GP's cognitions regarding HPV
24 vaccination might have changed. This was not formally assessed in our analysis.

25 The quality of this review can be acknowledged regarding the accuracy of the literature
26 research and the use of recommended review guidelines and tools to assess bias. Compared
27 with other literature reviews that explore cognitions related to HPV vaccination and focus on
28 attitudes and knowledge, our review goes further by (a) using the RAA theoretical framework
29 (b) addressing methodological differences between studies, (c) providing an overview of the
30 impacts of all these cognitions on vaccination behaviour, and (d) focusing on only one type of
31 health providers, i.e., GPs. The results of this review could easily be used and adapted in
32 countries that have similar health policies and similar HPV vaccination issues.

1 **Conclusion**

2 To our knowledge, no GP-level interventions have been successful in improving HPV uptake
3 rates in France. Our results will inform the development of a professional educational
4 intervention on HPV vaccination targeting GPs in France. HPV vaccination is one of the main
5 pillars of the recently launched WHO initiative to eliminate cervical cancer around the world
6 and removing barriers to vaccination in different settings and from different perspective
7 including health professionals is of paramount importance for success.

8 **Conflicts of interests**

9 None to declare.

10 **Funding information**

11 P. Villain/IARC obtained funding from the French National Cancer Institute (INCa, grant nr.
12 2016-009) and Métropole de Lyon / Cancéropôle Lyon Auvergne-Rhône-Alpes (CLARA).
13 The sponsors had no involvement in the study design, collection, analysis and interpretation
14 of data, the writing of the manuscript, or the decision to submit the manuscript for
15 publication.

16 **Acknowledgements**

17 The authors are grateful to Dr. Karen Muller who helped to stylistically edit the manuscript
18 and to K. Pitaksaringkarn who helped in the manuscript submission. The authors are also
19 grateful to their colleagues from IARC, especially Dr P. Basu, and GRePS, who kindly
20 reviewed the protocol and provided constructive comments.

21 **References**

- 22 1. Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al. Global estimates of
23 human papillomavirus vaccination coverage by region and income level: a pooled analysis. *The*
24 *Lancet Global health*. 2016;4(7):e453-63.
- 25 2. Santé Publique France. HPV vaccination coverage in France by age group.
26 [https://www.santepubliquefrance.fr/determinants-de-sante/vaccination/articles/donnees-de-](https://www.santepubliquefrance.fr/determinants-de-sante/vaccination/articles/donnees-de-couverture-vaccinale-papillomavirus-humains-hpv-par-groupe-d-age)
27 [couverture-vaccinale-papillomavirus-humains-hpv-par-groupe-d-age](https://www.santepubliquefrance.fr/determinants-de-sante/vaccination/articles/donnees-de-couverture-vaccinale-papillomavirus-humains-hpv-par-groupe-d-age). Accessed 07.04.2020.
- 28 3. Verrier F, Gautier A, Quelet S, Bonmarin I, et le groupe Baromètre de Santé publique France
29 2016. Infections à papillomavirus humain : influence des perceptions de la maladie et du vaccin sur le
30 statut vaccinal. (Influence of perceptions of disease and vaccine on immunization status). *Bull*
31 *Epidémiol Hebd*. 2019; 22-23: 450-56. [https://www.santepubliquefrance.fr/revues/beh/bulletin-](https://www.santepubliquefrance.fr/revues/beh/bulletin-epidemiologique-hebdomadaire)
32 [epidemiologique-hebdomadaire](https://www.santepubliquefrance.fr/revues/beh/bulletin-epidemiologique-hebdomadaire). Accessed 11/03/2020.
- 33
- 34 4. Blondel C, Barret AS, Pelat C, Lucas E, Fonteneau L, Lévy-Bruhl D. Influence des facteurs
35 socioéconomiques sur la vaccination contre les infections à HPV chez les adolescentes en France.

- 1 (Influence of socioeconomic factors on human papillomavirus vaccine uptake in adolescent girls in
2 France). Bull Epidemiol Hebd. 2019;22-23:441-50.
3 <https://www.santepubliquefrance.fr/revues/beh/bulletin-epidemiologique-hebdomadaire>. Accessed
4 11/03/2020.
- 5 5. Institut National du Cancer (INCa). Enquete-de-perception-aupres-des-medecins-
6 generalistes-et-des-parents. [https://www.e-cancer.fr/Actualites-et-
7 evenements/Actualites/Vaccination-contre-les-HPV-enquete-de-perception-aupres-des-medecins-
8 generalistes-et-des-parents](https://www.e-cancer.fr/Actualites-et-evenements/Actualites/Vaccination-contre-les-HPV-enquete-de-perception-aupres-des-medecins-generalistes-et-des-parents). Accessed 07/04/2020.
- 9 6. Karafillakis E, Simas C, Jarrett C, Verger P, Peretti-Watel P, Dib F, et al. HPV vaccination in a
10 context of public mistrust and uncertainty: a systematic literature review of determinants of HPV
11 vaccine hesitancy in Europe. Human vaccines & immunotherapeutics. 2019;15(7-8):1615-27.
- 12 7. Newman PA, Logie CH, Lacombe-Duncan A, Baiden P, Tepjan S, Rubincam C, et al. Parents'
13 uptake of human papillomavirus vaccines for their children: a systematic review and meta-analysis of
14 observational studies. BMJ open. 2018;8(4):e019206.
- 15 8. Campana V, Cousin L, Terroba C, Alberti C. Interventions permettant d'augmenter la
16 couverture vaccinale du vaccin contre les papillomavirus humains. (Interventions to increase HPV
17 vaccination coverage). Bull Epidemiol Hebd. 2019; 22-23: 431-40.
18 <https://www.santepubliquefrance.fr/revues/beh/bulletin-epidemiologique-hebdomadaire>. Accessed
19 11/03/2020.
- 20 9. Fonteneau L, Barret AS, Lévy-Bruhl D. Évolution de la couverture vaccinale du vaccin contre le
21 papillomavirus en France –2008-2018. (HPV vaccination coverage in France -2008-2018). Bull
22 Epidemiol Hebd. 2019; 22-23:424-30. [https://www.santepubliquefrance.fr/revues/beh/bulletin-
23 epidemiologique-hebdomadaire](https://www.santepubliquefrance.fr/revues/beh/bulletin-epidemiologique-hebdomadaire). Accessed 11/03/2020.
- 24 10. HPV vaccination recommendation to be extended to boys. [https://www.has-
25 sante.fr/jcms/p_3116022/fr/recommandation-sur-l-elargissement-de-la-vaccination-contre-les-
26 papillomavirus-aux-garcons](https://www.has-sante.fr/jcms/p_3116022/fr/recommandation-sur-l-elargissement-de-la-vaccination-contre-les-papillomavirus-aux-garcons). Accessed 07/04/2020
- 27 11. Ministère des Solidarités et de la Santé, Santé publique France, Informations sur la
28 vaccination pour les professionnels de santé, France. [https://professionnels.vaccination-info-
29 service.fr/Mentions-Legales](https://professionnels.vaccination-info-service.fr/Mentions-Legales). Accessed 07/04/2020.
- 30 12. Rosen BL, Shepard A, Kahn JA. US Health Care Clinicians' Knowledge, Attitudes, and Practices
31 Regarding Human Papillomavirus Vaccination: A Qualitative Systematic Review. Academic Pediatrics.
32 2018; S53-S65
- 33 13. Herzog R, Álvarez-Pasquin MJ, Díaz C, Del Barrio JL, Estrada JM, Gil Á. Are healthcare workers'
34 intentions to vaccinate related to their knowledge, beliefs and attitudes? a systematic review. BMC
35 Public Health. 2013;13:154.
- 36 14. Ferrer HB, Audrey S, Trotter C, Hickman M. An appraisal of theoretical approaches to
37 examining behaviours in relation to Human Papillomavirus (HPV) vaccination of young women.
38 Preventive medicine. 2015;81:122-31.
- 39 15. Ajzen I. The theory of planned behavior. Organizational Behavior and Human Decision
40 Processes. 1991;50:179-211.
- 41 16. Fishbein M, Ajzen I. Predicting and changing behaviour: The reasoned action approach. New
42 York: Psychology Press. 2010:538.
- 43 17. McEachan R, Taylor N, Harrison R, Lawton R, Gardner P, Conner M. Meta-Analysis of the
44 Reasoned Action Approach (RAA) to Understanding Health Behaviors. Annals of Behavioral Medicine.
45 2016;50:592-612.
- 46 18. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews
47 and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535-b.
- 48 19. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality
49 of nonrandomized studies in meta-analyses. European journal of epidemiology. 2010;25(9):603-5.
- 50 20. Singh J. Critical appraisal skills programme. Journal of pharmacology and
51 Pharmacotherapeutics. 2013;4(1):76.

- 1 21. Seers K. Qualitative systematic reviews: their importance for our understanding of research
2 relevant to pain. *British journal of pain*. 2015;9(1):36-40.
- 3 22. Agrinier N, Le Maréchal M, Fressard L, Verger P, Pulcini C. Discrepancies between general
4 practitioners' vaccination recommendations for their patients and practices for their children. *Clinical
5 Microbiology and Infection*. 2017;23:311-7.
- 6 23. Barjhoux A, Glatigny S. Vaccination contre les infections à papillomavirus humains : pratique
7 et difficultés des médecins généralistes isérois (Vaccination against human papillomavirus infections:
8 practice and difficulties of general practitioners from Isère). [Medical dissertation]. Grenoble, France:
9 Université de Grenoble Alpes; 2009.
- 10 24. Bouvret P, Mouglin C, Pretet JL, Meurisse A, Bonnetain F, Fiteni F. [Practices and attitudes
11 regarding HPV vaccination among general practitioners from Besançon]. *Journal de gynécologie,
12 obstétrique et biologie de la reproduction*. 2016;45(8):972-8.
- 13 25. Casimont L. Opinion des médecins généralistes sur les nouvelles stratégies de prévention du
14 cancer du col de l'utérus. Particularités départementales du Maine et Loire (Opinion of general
15 practitioners on new strategies for cervical cancer prevention. Specificities of "Maine et Loire").
16 [Medical dissertation]. Nantes, France: Université de Nantes; 2015.
- 17 26. Chauvet C. Vaccination anti-HPV : évaluation de la pertinence d'outils d'aide à l'information
18 vaccinale enquête auprès des médecins généralistes de Côte d'Or. (HPV vaccination: evaluation of
19 information tools used by general practitioners from Côte d'Or). [Medical dissertation]. Dijon, France:
20 Université de Bourgogne; 2016.
- 21 27. Collange F, Fressard L, Pulcini C, Sebbah R, Peretti-Watel P, Verger P. General practitioners'
22 attitudes and behaviors toward HPV vaccination: A French national survey. *Vaccine*. 2016;34:762-8.
- 23 28. Degoue M. Place de la vaccination anti-HPV dans la pratique des médecins généralistes (HPV
24 vaccination in general practitioners' practice). [Medical dissertation]. Grenoble, France: Université de
25 Grenoble Alpes; 2019.
- 26 29. Erpeldinger S R-HV, Bousageon R, et al. Vaccination contre les infections à papillomavirus en
27 médecine générale. La décision de vacciner par le Gardasil® est-elle un choix éclairé? Enquête auprès
28 de 518 MG du Rhône. *Médecine (Vaccination against papillomavirus infections in general medicine.
29 Is the decision to vaccinate with Gardasil® an informed choice? Survey with 518 general practitioners
30 from Rhône)*. *Médecine* 8(4):185-9.
- 31 30. Gougenheim-Fretin L SM. Réticences vis-à-vis du vaccin contre le Human Papillomavirus et
32 solutions envisagées à partir d'une étude qualitative réalisée auprès de médecins traitants et de
33 parents d'adolescentes. (Barriers to Human Papillomavirus vaccine and solutions based on a
34 qualitative study conducted with general practitioners and parents of adolescent girls). [Medical
35 dissertation]. Lille, France: Université du Droit et de la Santé-Lille 2; 2014.
- 36 31. Houdjal L. Approche des représentations des médecins généralistes sur la vaccination anti-
37 HPV à l'aide d'un modèle évaluant les opinions, les pratiques et les informations délivrées aux
38 patients (General practitioners' representations regarding HPV vaccination using a model evaluating
39 opinions, practices and information provided to patients). [Medical dissertation]. Paris, France:
40 Université Pierre et Marie Curie; 2017.
- 41 32. Killian M, Detoc M, Berthelot P, Charles R, Gagneux-Brunon A, Lucht F, et al. Vaccine
42 hesitancy among general practitioners: evaluation and comparison of their immunisation practice for
43 themselves, their patients and their children. *European Journal of Clinical Microbiology and
44 Infectious Diseases*. 2016;35:1837-43.
- 45 33. Lamirand S. Vaccination anti-papillomavirus humain (HPV): influence des nouvelles
46 recommandations et des médias sur la pratique des médecins généralistes. [Medical dissertation].
47 Nancy, France: Université de Lorraine; 2015.
- 48 34. Lasset C, Kalecinski J, Regnier V, Barone G, Leocmach Y, Vanhems P, et al. Practices and
49 opinions regarding HPV vaccination among French general practitioners: evaluation through two
50 cross-sectional studies in 2007 and 2010. *International journal of public health*. 2014;59(3):519-28.

- 1 35. Leicht A. Quels sont les freins des médecins généralistes à la vaccination contre les
2 papillomavirus ?(What are general practitioners'barriers to vaccinate against HPV?). [Medical
3 dissertation]. Lille, France: Université du Droit et de la Santé-Lille 2; 2016.
- 4 36. Lutringer-Magnin D, Kalecinski J, Barone G, Leocmach Y, Regnier V, Jacquard AC, et al. Human
5 papillomavirus (HPV) vaccination: Perception and practice among French general practitioners in the
6 year since licensing. *Vaccine*. 2011;29:5322-8.
- 7 37. Manolitsi T. Exploration des freins des médecins généralistes des Yvelines par rapport à la
8 vaccination anti-HPV (Exploration of the obstacles of general practitioners in Yvelines with regard to
9 anti-HPV vaccination). [Medical dissertation]. Versailles, France: Université de Versailles; 2012.
- 10 38. Martinez L, Tugaut B, Raineri F, Arnould B, Seyler D, Arnould P, et al. The commitment of
11 French general practitioners to vaccination: the DIVA study (Determinants of vaccination intentions).
12 *Sante Publique*. 2016;28(1):19-32.
- 13 39. Pelissier G, Bastides F. HPV vaccine and cervical cancer prevention in general practice. Survey
14 conducted among general practitioners in the French departments of Eure-et-Loir and Cher. *La Revue
15 du praticien*. 2008;58(19 Suppl):25-31.
- 16 40. Piana L, Noel G, Uters M, Laporte R, Minodier P. Standpoint and practice concerning the
17 human Papillomavirus vaccine among French family physicians. *Medecine et maladies infectieuses*.
18 2009;39:789-97.
- 19 41. Plessis A BC, Ducancelle A, Moulévrier P, Fanello S. Vaccination contre le papillomavirus et
20 médecins généralistes. Une enquête qualitative en Pays-de-Loire (Vaccination against papillomavirus
21 and general practitioners. A qualitative survey in Pays-de-Loire.) *Médecine*. 2012;8(9):26-30.
- 22 42. Raude J, Fressard L, Gautier A, Pulcini C, Peretti-Watel P, Verger P. Opening the 'Vaccine
23 Hesitancy' black box: how trust in institutions affects French GPs' vaccination practices. *Expert
24 Review of Vaccines*. 2016;15:937-48.
- 25 43. Sadki M. Vaccination anti-papillomavirus : perception du vaccin par les médecins généralistes
26 et attitudes adoptées face aux réticences qu'il suscite (HPV vaccination: general practitioners'
27 perceptions and attitudes towards patients' reluctance). [Medical dissertation]. Amiens, France:
28 Université de Picardie; 2016.
- 29 44. Thierry P, Lasserre A, Rossignol L, Kerneis S, Blaizeau F, Stheneur C, et al. Human
30 Papillomavirus vaccination in general practice in France, three years after the implementation of a
31 targeted vaccine recommendation based on age and sexual history. *Human vaccines &
32 immunotherapeutics*. 2016;12(2):528-33.
- 33 45. Tutala M. Evaluation de l'impact des praticiens sur la couverture vaccinale HPV en Occitanie
34 (Evaluation of General practitioners' impact in HPV vaccination coverage in Occitanie) [Medical
35 dissertation]: Toulouse, France: Université de Toulouse III Paul Sabatier; 2019.
- 36 46. Verger P, Fressard L, Collange F, Gautier A, Jestin C, Launay O, et al. Vaccine Hesitancy Among
37 General Practitioners and Its Determinants During Controversies: A National Cross-sectional Survey in
38 France. *EBioMedicine*. 2015;2:891-7.
- 39 47. David G. Risques et principe de précaution en matière médicale. *Les Cahiers du Centre
40 Georges Canguilhem*. 2009;3(1):107-17.
- 41 48. McSherry LA, O'Leary E, Dombrowski SU, Francis JJ, Martin CM, O'Leary JJ, et al. Which
42 primary care practitioners have poor human papillomavirus (HPV) knowledge? A step towards
43 informing the development of professional education initiatives. *PloS one*. 2018;13(12):e0208482.
- 44 49. Chaput H, Monziols M, Fressard L, Verger P, Ventelou B, Zaytseva A. Deux tiers des médecins
45 généralistes libéraux déclarent travailler au moins 50 heures par semaine (Two-thirds of GPs report
46 working at least 50 hours a week). *Études et résultats*. 2019; 1113. [https://drees.solidarites-
47 sante.gouv.fr/etudes-et-statistiques/publications/etudes-et-resultats/article/deux-tiers-des-
48 medecins-generalistes-liberaux-declarent-travailler-au-moins-50](https://drees.solidarites-sante.gouv.fr/etudes-et-statistiques/publications/etudes-et-resultats/article/deux-tiers-des-medecins-generalistes-liberaux-declarent-travailler-au-moins-50) .Accessed 11/03/2020.
- 49 50. Stroebe W. *Social psychology and health*: McGraw-Hill Education (UK); 2011.
- 50 51. Marewski JN, Gigerenzer G. Heuristic decision making in medicine. *Dialogues in clinical
51 neuroscience*. 2012;14(1):77-89.

- 1 52. Vollrath K, Thul S, Holcombe J. Meaningful Methods for Increasing Human Papillomavirus
2 Vaccination Rates: An Integrative Literature Review. *Journal of pediatric health care : official*
3 *publication of National Association of Pediatric Nurse Associates & Practitioners.* 2018;32(2):119-32.
- 4 53. Jakoubovitch S, Bournot MC, Cercier E, Tuffreau. Les emplois du temps des medecins
5 generalistes. Études et résultats [Internet]. 2012; 797. [https://drees.solidarites-sante.gouv.fr/etudes-](https://drees.solidarites-sante.gouv.fr/etudes-et-statistiques/publications/etudes-et-resultats/article/les-emplois-du-temps-des-medecins-generalistes)
6 [et-statistiques/publications/etudes-et-resultats/article/les-emplois-du-temps-des-medecins-](https://drees.solidarites-sante.gouv.fr/etudes-et-statistiques/publications/etudes-et-resultats/article/les-emplois-du-temps-des-medecins-generalistes)
7 [generalistes.](https://drees.solidarites-sante.gouv.fr/etudes-et-statistiques/publications/etudes-et-resultats/article/les-emplois-du-temps-des-medecins-generalistes) Accessed 07/04/2020.
- 8 54. Kernéis S, Jacquet C, Bannay A, May T, Launay O, Verger P, Pulcini C; EDUVAC Study Group.
9 Vaccine Education of Medical Students: A Nationwide Cross-sectional Survey. *Am J Prev Med.* 2017
10 ;53(3):e97-e104.
- 11 55. Keating NL. Peer Influence and Opportunities for Physician Behavior Change. *Journal of the*
12 *National Cancer Institute.* 2017;109(8).
- 13 56. Brewer NT, Hall ME, Malo TL, Gilkey MB, Quinn B, Lathren C. Announcements Versus
14 Conversations to Improve HPV Vaccination Coverage: A Randomized Trial. *Pediatrics.* 2017;139(1).
- 15 57. Reno JE, O'Leary S, Garrett K, Pyrzanowski J, Lockhart S, Campagna E, et al. Improving
16 Provider Communication about HPV Vaccines for Vaccine-Hesitant Parents Through the Use of
17 Motivational Interviewing. *Journal of health communication.* 2018;23(4):313-20.
- 18 58. Malo TL, Hall ME, Brewer NT, Lathren CR, Gilkey MB. Why is announcement training more
19 effective than conversation training for introducing HPV vaccination? A theory-based investigation.
20 *Implement Sci.* 2018;13(1):57.
- 21 59. Passmore J. Motivational interviewing: reflecting on ethical decisions in MI. Source: *The*
22 *Coaching Psychologist.* 2013;9(2):2.
- 23 60. Malo TL, Ali KN, Sutton SK, Perkins RB, Giuliano AR, Vadaparampil ST. The content and
24 context of physicians' communication with males about human papillomavirus vaccination. *Human*
25 *vaccines & immunotherapeutics.* 2016;12(6):1511-8.
- 26 61. Basu P, Muwonge R, Bhatla N, Nene BM, Joshi S, Esmey PO, et al. Two-dose recommendation
27 for Human Papillomavirus vaccine can be extended up to 18 years - updated evidence from Indian
28 follow-up cohort study. *Papillomavirus research (Amsterdam, Netherlands).* 2019;7:75-81.

29

30